相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs
Y. H. Lee et al.
ZEITSCHRIFT FUR RHEUMATOLOGIE (2021)
The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases
William Damsky et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)
JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib
Paqui G. Traves et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
JAK inhibitors alter NK cell functions and may impair immunosurveillance against lymphomagenesis
Gaetane Nocturne et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors
Yukihiro Kitanaga et al.
RHEUMATOLOGY (2020)
Cellular cytokine receptor signaling and ATM pathway intersections affect hepatic DNA repair
Priya Gupta et al.
CYTOKINE (2020)
Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis
Janet Pope et al.
ADVANCES IN THERAPY (2020)
Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials
Yoshiya Tanaka et al.
EXPERT OPINION ON PHARMACOTHERAPY (2020)
Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease
Pavine L. C. Lefevre et al.
JOURNAL OF CROHNS & COLITIS (2020)
Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study
Hideto Kameda et al.
RHEUMATOLOGY (2020)
Increased Sensitivity of PBMCs Isolated from Patients with Rheumatoid Arthritis to DNA Damaging Agents Is Connected with Inefficient DNA Repair
Grzegorz Galita et al.
JOURNAL OF CLINICAL MEDICINE (2020)
JAK-STAT pathway targeting for the treatment of inflammatory bowel disease
Azucena Salas et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
STAT3 Contributes to Radioresistance in Cancer
Xuehai Wang et al.
FRONTIERS IN ONCOLOGY (2020)
JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future
Jacopo Angelini et al.
BIOMOLECULES (2020)
The IL-2-IL-2 receptor pathway in health and disease: The role of the soluble IL-2 receptor
Jan Damoiseaux
CLINICAL IMMUNOLOGY (2020)
Cytokines, JAK-STAT Signaling and Radiation-Induced DNA Repair in Solid Tumors: Novel Opportunities for Radiation Therapy
William A. Hall et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2020)
STAT3, the Challenge for Chemotherapeutic and Radiotherapeutic Efficacy
Ping-Lian Yang et al.
CANCERS (2020)
JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data
Robert Harrington et al.
JOURNAL OF INFLAMMATION RESEARCH (2020)
Studying DNA Double-Strand Break Repair: An Ever-Growing Toolbox
Alexandra C. Vitor et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2020)
Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials
Jacqueline M. Tarrant et al.
RHEUMATOLOGY AND THERAPY (2020)
DNA damage accumulation, defective chromatin organization and deficient DNA repair capacity in patients with rheumatoid arthritis
Vassilis L. Souliotis et al.
CLINICAL IMMUNOLOGY (2019)
Peficitinib: First Global Approval
Anthony Markham et al.
DRUGS (2019)
JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy
Elisa Gremese et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2019)
Role of janus kinase inhibitors in the treatment of rheumatic diseases
K. Krueger
INTERNIST (2019)
The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors
Katie Bechman et al.
PHARMACOLOGICAL RESEARCH (2019)
Methotrexate an Old Drug with New Tricks
Yosra Bedoui et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Selective Janus kinase inhibitors come of age
John J. O'Shea et al.
NATURE REVIEWS RHEUMATOLOGY (2019)
Clinical significance of Janus Kinase inhibitor selectivity
Ernest H. Choy
RHEUMATOLOGY (2019)
Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations
Iain B. McInnes et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition
Martin E. Dowty et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2019)
STAT5A/BBlockade Sensitizes Prostate Cancer to Radiation through Inhibition of RAD51 and DNA Repair
Cristina Maranto et al.
CLINICAL CANCER RESEARCH (2018)
Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers
Kent J. Weinhold et al.
CLINICAL IMMUNOLOGY (2018)
DNA damage, metabolism and aging in pro-inflammatory T cells Rheumatoid arthritis as a model system
Yinyin Li et al.
EXPERIMENTAL GERONTOLOGY (2018)
Rheumatoid arthritis
Josef S. Smolen et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
DNA Damage Response Signals Transduce Stress From Rheumatoid Arthritis Risk Factors Into T Cell Dysfunction
Lan Shao
FRONTIERS IN IMMUNOLOGY (2018)
In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)
Julie M. Parmentier et al.
BMC RHEUMATOLOGY (2018)
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Daniella M. Schwartz et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
TIMELINE Managing rheumatic and musculoskeletal diseases - past, present and future
Gerd R. Burmester et al.
NATURE REVIEWS RHEUMATOLOGY (2017)
The emerging safety profile of JAK inhibitors in rheumatic disease
Kevin L. Winthrop
NATURE REVIEWS RHEUMATOLOGY (2017)
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials
Frederic Vanhoutte et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms
Margaret Nieborowska-Skorska et al.
BLOOD (2017)
Mechanisms and consequences of Jak-STAT signaling in the immune system
Alejandro V. Villarino et al.
NATURE IMMUNOLOGY (2017)
Developments with investigational Janus kinase inhibitors for rheumatoid arthritis
Luca Semerano et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)
Time-Dependent Regulation of IL-2R α-Chain (CD25) Expression by TCR Signal Strength and IL-2-Induced STAT5 Signaling in Activated Human Blood T Lymphocytes
Alla N. Shatrova et al.
PLOS ONE (2016)
Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models
Alessia Bottos et al.
NATURE COMMUNICATIONS (2016)
Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Mark C. Genovese et al.
ARTHRITIS & RHEUMATOLOGY (2016)
How cancer cells hijack DNA double-strand break repair pathways to gain genomic instability
Penny A. Jeggo et al.
BIOCHEMICAL JOURNAL (2015)
Enhancement of Cetuximab-Induced Radiosensitization by JAK-1 Inhibition
James A. Bonner et al.
BMC CANCER (2015)
JAK1/2 inhibition impairs T cell function invitro and in patients with myeloproliferative neoplasms
Sowmya Parampalli Yajnanarayana et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
DNA damage foci: Meaning and significance
Kai Rothkamm et al.
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS (2015)
Multiple facets of histone variant H2AX: a DNA double-strand-break marker with several biological functions
Valentina Turinetto et al.
NUCLEIC ACIDS RESEARCH (2015)
Methotrexate Is a JAK/STAT Pathway Inhibitor
Sally Thomas et al.
PLOS ONE (2015)
Three decades of low-dose methotrexate in rheumatoid arthritis: Can we predict toxicity?
Vasco C. Romao et al.
IMMUNOLOGIC RESEARCH (2014)
STAT3: A Novel Molecular Mediator of Resistance to Chemoradiotherapy
Melanie Spitzner et al.
CANCERS (2014)
Fully Automated Analysis of Chemically Induced γH2AX Foci in Human Peripheral Blood Mononuclear Cells by Indirect Immunofluorescence
Annika Willitzki et al.
CYTOMETRY PART A (2013)
Flow Cytometric Quantification of All Phases of the Cell Cycle and Apoptosis in a Two-Color Fluorescence Plot
Christine Vignon et al.
PLOS ONE (2013)
JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease
John J. O'Shea et al.
IMMUNITY (2012)
STAT3 modulates the DNA damage response pathway
Sean P. Barry et al.
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY (2010)
Kinetics and dose-response of residual 53BP1/gamma-H2AX foci: Co-localization, relationship with DSB repair and clonogenic survival
E. Markova et al.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY (2007)
Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines
S Herman et al.
INFLAMMATION RESEARCH (2005)
分享论文
